A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. - Wikidata - awgldk - TriplyDB

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

http://www.wikidata.org/entity/Q36934749

about

Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS)Contemporary approaches for imaging skeletal metastasis Anti-angiogenesis in prostate cancer: knocked down but not out Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Bone Metastases: An Overview.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis The role of epithelial plasticity in prostate cancer dissemination and treatment resistance CTC enumeration and characterization: moving toward personalized medicine.A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.Development of cabozantinib for the treatment of prostate cancer.Circulating tumour cells-monitoring treatment response in prostate cancer.Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.A phase I study of cabozantinib (XL184) in patients with renal cell cancer.Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Cabozantinib in genitourinary malignancies.Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.Circulating tumor cells in prostate cancer: Precision diagnosis and therapy MET expression during prostate cancer progression.Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.[New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy].

P2860

Q26747566-C64B17DC-413D-406E-88D6-F960AE47C89A Q26798170-E13D35D6-2DC7-4713-913E-279E1D2EBBD2 Q26851183-1643B317-9317-4CB8-8CEC-A04C4A9ED0E1 Q28074834-1106CF69-2CE3-4D45-992C-7C22A1EA05EE Q28082793-4D4D9CF1-C124-41E5-A00C-1304FDBCC48D Q33727278-EEA4E5B4-1739-41B7-A0DA-59C5BA8A8D21 Q33769437-A6544F63-0D95-458E-9E7C-51419AD4BE5B Q33880064-890D18A4-CD82-4BF3-A499-9AF9D7F46943 Q34108738-8E529CD8-AB45-44F4-8D94-063353B8F274 Q34330748-609F1744-140E-4377-BEEA-5F6703EDA1A8 Q34448130-6CAD8C4C-D68D-44ED-810C-B1144C3592C9 Q34505037-8D86D986-780B-468E-98CF-9F0626B6C431 Q34577724-606FF520-BB4B-45B4-84E6-DF136024AE43 Q34657338-9897E42A-3796-4E95-869D-38FDD2202994 Q34987693-C43D99EF-9BDE-4DC5-A792-646BCCF9EA05 Q35252908-4D74AE64-7AA6-4E9C-BBD6-E3228B0F3B4B Q35985270-5F879BCE-E9C9-4DA6-AB17-9D3A76D844D0 Q36051783-58815503-74EE-4386-99AA-1A91015C36D8 Q36156854-37ACE849-0FD9-4557-A7E8-3096B2CC13FB Q36436763-40EF65FB-3B86-41E5-9471-9D238C7C9B50 Q36931715-62EC7A49-C3F5-4BC6-A7C7-956558BFC382 Q37166534-07A80105-C7E5-4415-9055-7C445611230D Q37665068-71E6FEE9-897A-4E38-9058-41EA72AE4534 Q38160757-DEC150A6-492D-4D91-BF81-9013E10E9169 Q38177689-DB614843-DA26-4748-847B-D01CD3FFA807 Q38208820-5602F9F1-B579-491B-9C6B-6D9755ADA396 Q38211361-339BE921-5B6F-449B-84FF-73695E74F30B Q38244522-CA6E9937-5531-49D8-999F-B400394E5B92 Q38263563-CD95D508-EA5D-47D0-8687-0FDD17486A1B Q38430335-D14A777B-ADE7-42E7-8E7A-BE3872FFA5A9 Q38723404-8B40B480-5524-4C34-A94C-448994518165 Q38746778-E1C3BF40-1780-4AC3-8C4C-24A27F3D5538 Q38795560-873BC85B-F106-4787-87DE-1F61524A17CD Q38822335-B09A6707-FC66-410B-B208-209E368148DC Q38907580-E9377686-1750-4A5C-A08E-50C9F5F26279 Q41142322-8088CFC3-9493-4271-B60D-D4D08E230DE8 Q41418443-FAB30361-4A70-42B0-9EE0-ADA423E60A5E Q42530532-1DEB07C1-1F21-4EE9-A6D7-EEBE20D9C334 Q47940756-B2EC7ABB-5AF2-4344-A436-4646106A69BE Q54685484-AA49E5F8-C489-44B8-95D9-8042ABBD49D1

P2860

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

http://www.wikidata.org/entity/Q36934749

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

A dose-ranging study of caboza ...... te cancer and bone metastases.

@en

type

label

A dose-ranging study of caboza ...... te cancer and bone metastases.

@en

prefLabel

A dose-ranging study of caboza ...... te cancer and bone metastases.

@en

P1433

Q36934749-3D63CF40-2E1E-49CA-9F84-43F105EB1C60

P1476

Q36934749-EFCCC810-12E0-4B2F-9991-024747E3348D

P2093

Q36934749-061A6D92-5A34-403F-929F-1C4F462C9FF4

Q36934749-22B174B4-9BDA-4BD8-A7EC-0CB185CC0096

Q36934749-689ED275-9780-4125-94A2-7404F6B995B6

Q36934749-6E78D735-6CFB-4C99-8DBA-7F8328B72221

Q36934749-719B8D81-FCBB-4E27-BE6F-3F4838D457CB

Q36934749-79A51487-381A-43E2-97E6-1C69D88D9A9E

Q36934749-B8A2BAF8-8AF0-445D-8795-75E35432F31C

Q36934749-C907DFD3-076E-4EC5-97F7-8FDB7D6F0E10

Q36934749-CA4E18A2-416C-49B0-BBD1-6EDE671F7A18

Q36934749-D2124A9E-4742-48D6-AFC4-921DCF174756

P2860

Q36934749-0F6F1380-3F99-4358-8C97-2136A8653061

Q36934749-269E9FFF-58C1-46D9-B1A7-F0F390882609

Q36934749-2D79035C-C0AF-4E5B-8844-67BBAC3FDAF8

Q36934749-2E37F824-CB3A-438A-B628-D172D87E9C52

Q36934749-37C94443-E9D1-43AE-8E73-F614DB2A584A

Q36934749-391771C3-A9A4-4C44-BB1C-F9C8234C3F3A

Q36934749-4561DB31-9E27-42E1-BD0C-138C5FBA903B

Q36934749-54589093-E655-4C6B-B771-43E1DF34F5FB

Q36934749-5F72AA6E-396A-4EAB-915F-6C24A9E6ED65

Q36934749-8B3E105D-4DD1-450D-A2A6-9323B3E25C1A

P304

Q36934749-BFEE6944-2BF6-4408-9642-11CD5CAD3CC3

P31

Q36934749-87354AE7-CCE2-48DC-BA3B-742B559A1616

P356

Q36934749-6E90160C-72DE-47E4-B974-AA007513243A

P407

Q36934749-DE5BB95E-1C6F-403F-A900-FB055AF985C8

P433

Q36934749-885E58FC-1D44-4568-8BF0-527D01895A39

P478

Q36934749-5EE3F92D-0A52-47BB-A357-8F502A3D0B60

P577

Q36934749-60B4E5C9-F4B9-48AF-870C-A194B5907CB1

P698

Q36934749-2988A253-FEE1-4251-846D-02C44598BB6A

P932

Q36934749-D540168B-2333-4DEE-B0D5-172C5E56DCAE

P356

1078-0432.CCR-13-0319

P1433

Clinical Cancer Research

P1476

A dose-ranging study of caboza ...... te cancer and bone metastases.

@en

P2093

Carol A Gurski

http://www.w3.org/2001/XMLSchema#string

Daniel A Haber

http://www.w3.org/2001/XMLSchema#string

David T Miyamoto

http://www.w3.org/2001/XMLSchema#string

Jonathan G Goldin

http://www.w3.org/2001/XMLSchema#string

M Dror Michaelson

http://www.w3.org/2001/XMLSchema#string

Malgorzata E Smas

http://www.w3.org/2001/XMLSchema#string

Matthew R Smith

http://www.w3.org/2001/XMLSchema#string

Philip J Saylor

http://www.w3.org/2001/XMLSchema#string

Richard J Lee

http://www.w3.org/2001/XMLSchema#string

S Michael Rothenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

A three-outcome design for phase II clinical trials.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

High expression of the Met receptor in prostate cancer metastasis to bone.

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

P304

3088-3094

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0319

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23553848

http://www.w3.org/2001/XMLSchema#string

P932

3684567

http://www.w3.org/2001/XMLSchema#string